Abstract
This study was aimed to describe changes of Disease-Modifying Treatments (DMT) in an Italian cohort of patients with multiple sclerosis (MS) and to identify predictors of therapeutic modifications. Patients with MS and treated with the first-line injectable DMT (interferons-IFNs or glatiramer) between 1/7/2009 and 31/10/2012 were selected from administrative databases of the MS Center of Cagliari (Sardinia, Italy). Socio-demographic, therapeutic, and clinical information was collected in the 6 months preceding the index date. All patients were followed for 36 months to evaluate therapeutic changes in terms of non-adherence, switch, temporary discontinuation, and permanent interruption. Predictors of changes were estimated by multivariable regression models. Data on 1698 patients were collected: glatiramer was prescribed in 27% of cases, IFNβ-1b in 22%, IFNβ-1a-im in 20%, IFNβ-1a-sc-44mcg in 19%, and IFNβ-1a-sc-22mcg in 12%. Non-adherence was observed in 25% of cases, therapeutic switch in 30%, discontinuation in 37%, and permanent interruption in 28%. The risk of non-adherence was higher for IFNβ-1b, compared with IFNβ-1a-im (adjOR = 1.73). Therapeutic switch occurred especially in patients recently diagnosed (each year from diagnosis causes a decrease of this risk adjHR = 0.97); the risk of discontinuation was higher with EDSS = 4–6 and 7–9 (adjHR = 1.52 and 4.42, respectively). The risk of permanent interruption increased with the augmentation of disability (adjHR = 1.67 and 5.43 for EDSS 4–6 and 7–9). This study mirrored a detailed framework of DMT prescription and identified factors related to changes in the MS therapy. These findings could support healthcare providers in the evaluation and maximization of benefits associated with a long-term DMT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Piehl F (2014) A changing treatment landscape for multiple sclerosis: challenges and opportunities. J Intern Med 275(4):364–381
Wingerchuk DM, Carter JL (2014) Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 89(2):225–240
Fox RJ, Arnold DL (2009) Seeing injectable MS therapies differently: they are more similar than different. Neurology 72(23):1972–1973
Patti F (2010) Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 4:1–9
Siger M, Durko A, Nicpan A, Konarska M, Grudziecka M, Selmaj K (2011) Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J Neurol Sci 303(1–2):50–52
Reynolds MW, Stephen R, Seaman C, Rajagopalan K (2010) Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 26(3):663–674
Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA (2010) Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 30(2):89–100
Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC (2011) The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 18(1):69–77
Wong J, Gomes T, Mamdani M, Manno M, O’Connor PW (2011) Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci 38(3):429–433
Reynolds MW, Stephen R, Seaman C, Rajagopalan K (2010) Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 13(1):90–98
Atlas of MS 2013: mapping of multiple scleoris around the world (2013) https://www.msif.org/wpcontent/uploads/2014/09/Atlas-of-MS.pdf. Accessed 04 Jan 2017
Cocco E, Sardu C, Massa R, Mamusa E, Musu L, Ferrigno P, Melis M, Montomoli C, Ferretti V, Coghe G, Fenu G, Frau J, Lorefice L, Carboni N, Contu P, Marrosu MG (2011) Epidemiology of multiple sclerosis in south-western Sardinia. Mult Scler 17(11):1282–1289
Trojano M, Liguori M, Paolicelli D, Zimatore GB, De RF, Avolio C, Giuliani F, Fuiani A, Livrea P (2003) Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 9(5):451–457
AIFA Guideline for the classification and conduction of the observational studies on medicines (2010) https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf. Accessed 04 Jan 2017
Steiner JF, Prochazka AV (1997) The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 50(1):105–116
Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, Fisk JD, Evans C, Beland SG, Kulaga S, Dykeman J, Wolfson C, Koch MW, Marrie RA (2013) Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 13:128. doi:10.1186/1471-2377-13-128.:128-13
Jokubaitis VG, Spelman T, Lechner-Scott J, Barnett M, Shaw C, Vucic S, Liew D, Butzkueven H, Slee M (2013) The australian multiple sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PLoS One 8(3):e59694
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Degli Esposti, L., Piccinni, C., Sangiorgi, D. et al. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurol Sci 38, 589–594 (2017). https://doi.org/10.1007/s10072-016-2806-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-016-2806-4